IP Library › Granted Patent US 12,649,771
Granted Patent B2
US 12,649,771 · App. 17/996,436 · Granted Jun 9, 2026

Microorganism expressing vasoactive intestinal peptide, and use thereof

Inventors: Ji Yoon Song (Seongnam-si, KR); Hyo Jeong Choi (Anyang-si, KR); Hyeon Jin Noh (Seoul, KR); Young Ha Park (Suwon-si, KR); Yi Reh Jung (Uiwang-si, KR)
Assignee: MEDYTOX INC.
C07K14/57563A61K35/747A61P1/00A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,649,771
App. No.
17/996,436
Granted
Jun 9, 2026
Kind
B2
Abstract

Provided are a recombinant microorganism expressing a vasoactive intestinal peptide (VIP) gene, and a composition including the microorganism for preventing or treating a disease causing damage to the gastrointestinal tract.

Claims (9)

1 . A recombinant microorganism of the genus Lactobacillus , in which a constitutive promoter and an exogenous gene are introduced and a protease is inactivated, wherein the exogenous gene is operably linked to the constitutive promoter and encodes a vasoactive intestinal peptide (VIP), wherein the inactivated protease is at least one selected from the group consisting of HtrA, PepN, ClpP, and Lon, and wherein the microorganism is Lactobacillus paracasei, Lactobacillus brevis , or Lactobacillus plantarum.

2 . The microorganism of claim 1 , further comprising a signal sequence operably linked between the constitutive promoter and the exogenous gene.

3 . The microorganism of claim 1 , wherein gene encoding the protease is replaced with an exogenous gene operably linked to the constitutive promoter and encoding the VIP.

4 . The microorganism of claim 1 , wherein the microorganism is an auxotroph.

5 . The microorganism of claim 4 , wherein at least one gene selected from the group consisting of ribB, thyA, and glmS is deleted.

6 . A composition for treating a disease causing damage to gastrointestinal tract in humans, comprising the recombinant microorganism as set forth in claim 1 .

7 . The composition of claim 6 , wherein the disease is one causing inflammation of the gastrointestinal tract.

8 . The composition of claim 7 , wherein the disease is at least one selected from the group consisting of inflammatory bowel disease (IBD) and colitis.

9 . The composition of claim 8 , wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Mar 11, 2026
From: LIVEOME INC.
To: MEDYTOX INC.
Reel/Frame 074034/0013 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2022
From: SONG, JI YOON; CHOI, HYO JEONG; NOH, HYEON JIN; PARK, YOUNG HA; JUNG, YI REH
To: LIVEOME INC.
Reel/Frame 061450/0036 →
Priority Claims (1)
KR 10-2020-0047660 · Apr 20, 2020 · national
Continuity (1)
Related Publication 20240218039A1 · Jul 4, 2024
References Cited (48)
US 8748381B2 · Polk et al. · 2014 [cited by applicant]
US 9561262B2 · Georgopoulos et al. · 2017 [cited by applicant]
US 9700598B2 · Sadeghi et al. · 2017 [cited by applicant]
US 10064902B2 · Legrain-Raspaud et al. · 2018 [cited by applicant]
US 11046984B2 · Mccoy et al. · 2021 [cited by applicant]
US 20110150907A1 · Seegers et al. · 2011 [cited by applicant]
US 20160045557A1 · Legrain-Raspaud et al. · 2016 [cited by applicant]
US 20180008677A1 · Sadeghi et al. · 2018 [cited by applicant]
US 20190262420A1 · Shailubhai · 2019 [cited by applicant]
US 20200339637A1 · Kim et al. · 2020 [cited by applicant]
CN 108753670A · 2018 [cited by applicant]
JP 2000236873A · 2000 [cited by applicant]
JP 2002154976A · 2002 [cited by applicant]
JP 2006262724A · 2006 [cited by applicant]
JP 2015529453A · 2015 [cited by applicant]
JP 2016514670A · 2016 [cited by applicant]
JP 2017515455A · 2017 [cited by applicant]
KR 20120062777A · 2012 [cited by applicant]
KR 1020140000620A · 2014 [cited by applicant]
KR 20150095717A · 2015 [cited by applicant]
KR 101992345B1 · 2019 [cited by applicant]
WO 2008104890A2 · 2008 [cited by applicant]
WO 2011086172A1 · 2011 [cited by applicant]
WO 2014018596A2 · 2014 [cited by applicant]
WO 2018097402A1 · 2018 [cited by applicant]
WO 2019132231A1 · 2019 [cited by applicant]
Xu et al., CN 108753670 A—PTO English Machine Translation attached; total pp. 1-11. (Year: 2018). [cited by examiner]
A. Miyoshi et al., “Controlled Production of Stable Heterologous Proteins in Lactococcus Lactis”, Applied and Environmental Microbiology, Jun. 2002, p. 3141-3146. [cited by applicant]
1st Office Action issued dated Sep. 19, 2023 of Japanese Patent Application No. 2022-563907. [cited by applicant]
Chun-Lan Xu et al., “Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats”, World Journal of Gastroenterology, Feb. 14, 2018;24(b): 706-715. [cited by applicant]
European Search Report for European Patent Application No. 21793347.2 dated Mar. 22, 2024. [cited by applicant]
Manpreet Bains et al., “Vasoactive Intestinal Peptide Deficiency is associated with Altered Gut Microbiota Communities in Male and Female C57BL/6 Mice”, Frontiers in Microbiology, Dec. 2019, vol. 10, Article 2689, 1-14. [cited by applicant]
Mari Iwasaki et al., “Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]”, F1000Resarch, Sep. 12, 2019, 1-13. [cited by applicant]
C. Michon et al., “Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications,” Michon et al. Microb Cell Fact, 2016, pp. 1-16. [cited by applicant]
Catalina Abad et al., “Therapeutic Effects of Vasoactive Intestinal Peptide in theTrinitrobenzene Sulfonic Acid Mice Model of Crohn's Disease,” Gastroenterology, 2003, pp. 961-971, vol. 124. [cited by applicant]
Haryoung Poo et al., “Oral administration of human papillomavirus type 16 E7 displayedon Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice,” Int. J. Cancer, 2006, pp. 1702-1709, vol. 119. [cited by applicant]
Mays et al., Curr. Opin. Biotechnol, 53: 224-231 (2018, published Mar. 15, 2018). [cited by applicant]
Mario Delgado et al., “In Vivo Delivery of Lentiviral Vectors Expressing Vasoactive Intestinal Peptide Complementary DNA as Gene Therapy for Collagen-Induced Arthritis,” Arthritis & Rheumatism, Apr. 4, 2008, pp. 1026-10… [cited by applicant]
Rajasree et al., Ind. J. Geo-Marine Sc. 42(5): 766-775 (2015). [cited by applicant]
Sujin Bao, et al. “Distribution Dynamics of Recombinant Lactobacillus in the Gastrointestinal Tract of Neonatal Rats,” Plos One, Mar. 27, 2013, pp. 1-8 (e60007), vol. 8, Issue 3. [cited by applicant]
Valéria Dellaretti Guimarães et al., “Use of Native Lactococci as Vehicles for Delivery of DNA into Mammalian Epithelial Cells,” Applied and Environmental Microbiology, Nov. 2006, pp. 7091-7097, vol. 72, No. 11. [cited by applicant]
Wikipedia, https://en.wikipedia.org/wiki/M17_agar (accessed May 22, 2024). [cited by applicant]
Yan et al., Int. J Clin. Exp. Med. 8(11): 20245-20253 (2015). [cited by applicant]
Zachary Js Mays et al., “Synthetic biology in probiotic lactic acid bacteria: At the frontier of living therapeutics,” Current Opinion in Biotechnology, Mar. 15, 2018, pp. 224-231, vol. 53. [cited by applicant]
Kalpana Sriraman et al., HtrA is Essential for Efficient Secretion of Recombinant Proteins by Lactococcus lactis, Applied and Environmental Microbiology, Dec. 2008, p. 7442-7446. [cited by applicant]
Mengjin Liu et al., “The proteolytic system of lactic acid bacteria revisited: a genomic comparison”, Genomics 2010, 11:36. [cited by applicant]
Willem M. de Vos, “Gene expression systems for lactic acid bacteria”, Ecology and industrial microbiology, current Opinion in Microrbiology, 1999, 2, pp. 289-295. [cited by applicant]
Chunlan Xu et al., “Biosynthesis of Polysaccharides-Capped Selenium Nanoparticles Using Lactococcus lactis NZ9000 and Their Antioxidant and Anti-inflammatory Activities”, Frontiers in Microbiology, Jul. 1, 2019 vol. 10 … [cited by applicant]